{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T06:46:31Z","timestamp":1791960391852,"version":"4.3.4"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-026-01648-y","type":"journal-article","created":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:55:00Z","timestamp":1791939300000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Improving survival and narrowing age disparities in mantle cell lymphoma across therapeutic eras"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7306-8677","authenticated-orcid":false,"given":"Malak","family":"Munir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L.","family":"Vaughn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sravani","family":"Rimmalapudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8216-3457","authenticated-orcid":false,"given":"Narendranath","family":"Epperla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,13]]},"reference":[{"key":"1648_CR1","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/s41375-026-02942-1","volume":"40","author":"R Tavarozzi","year":"2026","unstructured":"Tavarozzi R, Maher N, Catania G, Zacchi G, D\u2019Andrea F, Sofia A, et al. Evolving therapeutic strategies in mantle cell lymphoma: advancements and future directions. Leukemia. 2026;40:857\u201371.","journal-title":"Leukemia"},{"key":"1648_CR2","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s13045-023-01496-4","volume":"16","author":"N Jain","year":"2023","unstructured":"Jain N, Mamgain M, Chowdhury SM, Jindal U, Sharma I, Sehgal L, et al. Beyond Bruton\u2019s tyrosine kinase inhibitors in mantle cell lymphoma: bispecific antibodies, antibody-drug conjugates, CAR T-cells, and novel agents. J Hematol Oncol. 2023;16:99.","journal-title":"J Hematol Oncol"},{"key":"1648_CR3","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMra2202672","volume":"386","author":"JO Armitage","year":"2022","unstructured":"Armitage JO, Longo DL. Mantle-cell lymphoma. N Engl J Med. 2022;386:2495\u2013506.","journal-title":"N Engl J Med"},{"key":"1648_CR4","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13045-020-00914-1","volume":"13","author":"W Hanel","year":"2020","unstructured":"Hanel W, Epperla N. Emerging therapies in mantle cell lymphoma. J Hematol Oncol. 2020;13:79.","journal-title":"J Hematol Oncol"},{"key":"1648_CR5","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382:1331\u201342.","journal-title":"N Engl J Med"},{"key":"1648_CR6","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1016\/S0140-6736(24)00184-3","volume":"403","author":"M Dreyling","year":"2024","unstructured":"Dreyling M, Doorduijn J, Gin\u00e9 E, Jerkeman M, Walewski J, Hutchings M, et al. Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network. Lancet. 2024;403:2293\u2013306.","journal-title":"Lancet"},{"key":"1648_CR7","doi-asserted-by":"crossref","unstructured":"Fenske TS, Wang XV, Till BG, Blum KA, Lunning M, Lazarus HM, et al. Lack of Benefit of Autologous Hematopoietic Cell Transplantation (auto-HCT) in Mantle Cell Lymphoma (MCL) Patients (pts) in First Complete Remission (CR) with Undetectable Minimal Residual Disease (uMRD): Initial Report from the ECOG-ACRIN EA4151 Phase 3 Randomized Trial. Blood. 2024;144:LBA-6-LBA-.","DOI":"10.1182\/blood-2024-212973"},{"key":"1648_CR8","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.1182\/bloodadvances.2021006934","volume":"6","author":"M Di","year":"2022","unstructured":"Di M, Cui C, Kothari SK, Zeidan AM, Podoltsev NA, Neparidze N, et al. Survival of mantle cell lymphoma in the era of Bruton tyrosine kinase inhibitors: a population-based analysis. Blood Adv. 2022;6:3339\u201342.","journal-title":"Blood Adv"},{"key":"1648_CR9","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1111\/bjh.14699","volume":"181","author":"N Epperla","year":"2018","unstructured":"Epperla N, Hamadani M, Fenske TS, Costa LJ. Incidence and survival trends in mantle cell lymphoma. Br J Haematol. 2018;181:703\u20136.","journal-title":"Br J Haematol"},{"key":"1648_CR10","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.3109\/10428194.2012.656628","volume":"53","author":"R Chandran","year":"2012","unstructured":"Chandran R, Gardiner SK, Simon M, Spurgeon SE. Survival trends in mantle cell lymphoma in the United States over 16 years 1992\u20132007. Leuk Lymphoma. 2012;53:1488\u201393.","journal-title":"Leuk Lymphoma"},{"key":"1648_CR11","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.canep.2018.12.002","volume":"58","author":"S Fu","year":"2019","unstructured":"Fu S, Wang M, Li R, Lairson DR, Zhao B, Du XL. Increase in survival for patients with mantle cell lymphoma in the era of novel agents in 1995\u20132013: findings from Texas and national SEER areas. Cancer Epidemiol. 2019;58:89\u201397.","journal-title":"Cancer Epidemiol"},{"key":"1648_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.588314","volume":"10","author":"H Wu","year":"2020","unstructured":"Wu H, Wang J, Zhang X, Yang H, Wang Y, Sun P, et al. Survival trends in patients under age 65 years with mantle cell lymphoma, 1995-2016: a SEER-based analysis. Front Oncol. 2020;10:588314.","journal-title":"Front Oncol"},{"key":"1648_CR13","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1182\/bloodadvances.2021005715","volume":"6","author":"A Castellino","year":"2022","unstructured":"Castellino A, Wang Y, Larson MC, Maurer MJ, Link BK, Farooq U, et al. Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes. Blood Adv. 2022;6:1350\u201360.","journal-title":"Blood Adv"},{"key":"1648_CR14","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/S0140-6736(17)33108-2","volume":"391","author":"M Wang","year":"2018","unstructured":"Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD, et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet. 2018;391:659\u201367.","journal-title":"Lancet"},{"key":"1648_CR15","doi-asserted-by":"publisher","first-page":"4216","DOI":"10.1158\/1078-0432.CCR-19-3703","volume":"26","author":"Y Song","year":"2020","unstructured":"Song Y, Zhou K, Zou D, Zhou J, Hu J, Yang H, et al. Treatment of patients with relapsed or refractory mantle-cell lymphoma with zanubrutinib, a selective inhibitor of Bruton\u2019s tyrosine kinase. Clin Cancer Res. 2020;26:4216\u201324.","journal-title":"Clin Cancer Res"},{"key":"1648_CR16","first-page":"1694","volume":"111","author":"L Jiang","year":"2026","unstructured":"Jiang L, Ladetto M, Hermine O, Kluin-Nelemans JC, Walewski J, Doorduijn J, et al. Marked survival gains in patients \u2264 65 years with advanced-stage mantle cell lymphoma: a pooled analysis of six randomized phase III trials, 1996\u20132020. Haematologica. 2026;111:1694\u2013704.","journal-title":"Haematologica"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01648-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01648-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01648-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T06:03:39Z","timestamp":1791957819000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01648-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,13]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1648"],"URL":"https:\/\/doi.org\/10.1038\/s41408-026-01648-y","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,13]]},"assertion":[{"value":"14 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The study was conducted in compliance with the Declaration of Helsinki. Given the nature of the study (population-based study from a public repository), this study was IRB exempt.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"As this was a retrospective study, informed consent was waived.","order":3,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"182"}}